citalopram and tramadol

Both drugs increase serotonergic activity in the central nervous system: citalopram blocks serotonin reuptake and tramadol both inhibits serotonin reuptake and promotes serotonin release. The combined effect may lead to excessive synaptic serotonin, precipitating serotonin syndrome. Additionally, citalopram inhibits CYP2D6, reducing conversion of tramadol to its active metabolite O-desmethyltramadol, which may diminish tramadol's analgesic effect. Both drugs can lower the seizure threshold, and citalopram carries a dose-dependent risk of QT prolongation, which tramadol may exacerbate. The pharmacodynamic interaction is synergistic and is the primary concern.

Patients may experience serotonin syndrome: agitation, confusion, fever, diaphoresis, tremor, hyperreflexia, clonus, and potentially life-threatening cardiovascular collapse. Seizures have been reported in patients taking this combination. The reduced formation of the active tramadol metabolite may result in inadequate pain relief and increase the temptation to escalate tramadol dose, further raising serotonin load. There is also an additive risk of QT prolongation and cardiac arrhythmias, especially with citalopram doses above 40 mg/day.

Avoid the combination where possible. If co-administration is necessary, use the lowest effective doses of both drugs, and prescribe with caution in patients with pre-existing seizure disorders or cardiac disease. Monitor the patient closely for signs of serotonin syndrome (especially during the first few days) and for seizures. Consider alternative analgesics such as paracetamol, NSAIDs, or non-serotonergic opioids (e.g., oxycodone, morphine) if appropriate. If citalopram dose exceeds 40 mg/day, reassess the need for tramadol. Advise patients to seek immediate medical attention if they develop symptoms such as confusion, muscle twitching, or increased sweating. An ECG may be warranted if there are other risk factors for QT prolongation.

This is a well-recognised interaction; multiple case reports and clinical studies have documented serotonin syndrome and seizures with the combination of SSRIs and tramadol. The pharmacokinetic component (CYP2D6 inhibition by citalopram) is supported by human studies, although the magnitude of effect varies between individuals. Practice guidelines recommend caution and close monitoring.